Investment Bank Mizuho Downgrades Qiagen, Alere | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Mizuho today lowered estimates on Qiagen, citing concerns about competition, higher cost assumptions, and an unsettled European market.

Separately, the bank also downgraded diagnostic firm Alere, citing expected cost increases stemming from the firm's molecular diagnostics ambitions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.